PRTX-100
- Generic Name
- PRTX-100
- Drug Type
- Small Molecule
- Background
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.
- Indication
Investigated for use/treatment in autoimmune diseases, inflammatory disorders (unspecified), rheumatoid arthritis, and thrombocytopenia.
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02566603
- Locations
- 🇫🇷
CH Lyon Sud, Pierre-Bénite, Lyon, France
🇫🇷Côte de Nacre Hospital, Caen, France
🇫🇷Mondor Hospital, Créteil, France
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02401061
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02330445
- Locations
- 🇺🇸
Protalex Investigational Site, Coeur d'Alene, Idaho, United States
Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01749787
- Locations
- 🇺🇸
Protalex Investigational Site, Allen, Texas, United States
🇺🇸Protalex Investigative Site, Los Angeles, California, United States
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
- Conditions
- Idiopathic Thrombocytopenic Purpura (ITP)
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Protalex, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00571467
- Locations
- 🇦🇺
St. George Hospital, Sydney, New South Wales, Australia
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺Royal Brisbane, Brisbane, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.